标题
Signaling Pathway Mediating Myeloma Cell Growth and Survival
作者
关键词
-
出版物
Cancers
Volume 13, Issue 2, Pages 216
出版商
MDPI AG
发表日期
2021-01-11
DOI
10.3390/cancers13020216
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications
- (2020) Daisuke Ogiya et al. BLOOD
- Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma
- (2020) Fazal Shirazi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Crosstalk of Hedgehog and mTORC1 Pathways
- (2020) Lasse Jonsgaard Larsen et al. Cells
- Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma
- (2019) Danielle Harmer et al. Frontiers in Endocrinology
- Aberrant Wnt signaling in multiple myeloma: molecular mechanisms and targeting options
- (2019) Harmen van Andel et al. LEUKEMIA
- Oral MEK 1/2 Inhibitor Trametinib in Combination with AKT Inhibitor GSK2141795 in Patients with Acute Myeloid Leukemia with RAS Mutations: A Phase II Study
- (2019) Brittany Knick Ragon et al. Clinical Lymphoma Myeloma & Leukemia
- Interleukin-6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in Multiple Myeloma
- (2019) Phyllis S.Y. Chong et al. CANCER RESEARCH
- PI3K/mTOR Pathway Inhibition: Opportunities in Oncology and Rare Genetic Diseases
- (2019) Petra Hillmann et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential
- (2018) Ingrid Spaan et al. Journal of Hematology & Oncology
- Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
- (2018) Sylvia Faict et al. Blood Cancer Journal
- MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway
- (2017) Ru-Fang Xiang et al. Cell Death & Disease
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma
- (2015) Yasuhiro Oki et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma
- (2015) B. Holkova et al. CLINICAL CANCER RESEARCH
- Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
- (2015) Jiro Kikuchi et al. JOURNAL OF CLINICAL INVESTIGATION
- The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells
- (2015) Di Zhu et al. NATURE MEDICINE
- BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
- (2015) E H Rustad et al. Blood Cancer Journal
- Rational combination treatment with histone deacetylase inhibitors and immunomodulatory drugs in multiple myeloma
- (2015) T Hideshima et al. Blood Cancer Journal
- Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells
- (2014) J. Wang et al. BLOOD
- Crosstalk between ERK, AKT, and cell survival
- (2014) Paul Dent CANCER BIOLOGY & THERAPY
- Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition
- (2014) N. Mimura et al. CANCER RESEARCH
- HGF, sIL-6R and TGF-β1 Play a Significant Role in the Progression of Multiple Myeloma
- (2014) Artur Jurczyszyn et al. Journal of Cancer
- A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
- (2014) Gordan Srkalovic et al. Cancer Medicine
- Crosstalk between PI3 Kinase/PDK1/Akt/Rac1 and Ras/Raf/MEK/ERK Pathways Downstream PDGF Receptor
- (2013) Emma Tabe Eko Niba et al. CELLULAR PHYSIOLOGY AND BIOCHEMISTRY
- BM mesenchymal stromal cell–derived exosomes facilitate multiple myeloma progression
- (2013) Aldo M. Roccaro et al. JOURNAL OF CLINICAL INVESTIGATION
- WNT signaling in bone homeostasis and disease: from human mutations to treatments
- (2013) Roland Baron et al. NATURE MEDICINE
- Targeting the BRAF V600E Mutation in Multiple Myeloma
- (2013) M. Andrulis et al. Cancer Discovery
- Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
- (2012) Andrzej J. Jakubowiak et al. BRITISH JOURNAL OF HAEMATOLOGY
- Anti-Myeloma Activity of Akt Inhibition Is Linked to the Activation Status of PI3K/Akt and MEK/ERK Pathway
- (2012) Vijay Ramakrishnan et al. PLoS One
- Sorafenib, a multikinase inhibitor, is effective in vitro against non-hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin
- (2011) Vijay Ramakrishnan et al. AMERICAN JOURNAL OF HEMATOLOGY
- The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
- (2011) Michelle C. Mendoza et al. TRENDS IN BIOCHEMICAL SCIENCES
- A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression
- (2010) C. M. Annunziata et al. BLOOD
- Biologic sequelae of I B kinase (IKK) inhibition in multiple myeloma: therapeutic implications
- (2009) T. Hideshima et al. BLOOD
- c-Met signaling promotes IL-6-induced myeloma cell proliferation
- (2009) Håkon Hov et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth
- (2008) Y.-W. Qiang et al. BLOOD
- Vicious cycle between myeloma cell binding to bone marrow stromal cells via VLA-4–VCAM-1 adhesion and macrophage inflammatory protein-1α and MIP-1β production
- (2008) Masahiro Abe et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Genetic aberrations and survival in plasma cell leukemia
- (2008) R E Tiedemann et al. LEUKEMIA
- Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma
- (2008) K Hatano et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now